Qube Research & Technologies Ltd - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 78 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$16,818
-81.8%
21,561
-78.5%
0.00%
Q2 2023$92,639
+77.7%
100,150
+109.4%
0.00%
Q1 2023$52,128
+32.2%
47,824
+77.1%
0.00%
Q4 2022$39,421
-47.4%
27,001
-38.6%
0.00%
-100.0%
Q2 2022$75,000
+127.3%
43,966
+261.4%
0.00%0.0%
Q1 2020$33,00012,1670.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2023
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$2,341,0003.33%
Matrix Capital Management Company, LP 38,974,185$66,256,0001.50%
NEA Management Company, LLC 17,082,612$29,040,0001.49%
Endurant Capital Management LP 1,824,065$3,101,0001.09%
Long Focus Capital Management, LLC 4,679,491$7,955,0000.83%
Key Client Fiduciary Advisors, LLC 416,166$707,0000.69%
PFM Health Sciences, LP 9,109,780$15,487,0000.59%
ACT CAPITAL MANAGEMENT, LLC 90,000$153,0000.21%
DAFNA Capital Management LLC 351,064$597,0000.16%
Rock Springs Capital Management LP 2,357,544$4,008,0000.12%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders